Accepted at 12:40 a.m. Mar, 06, 2024 by Cameron
Author: cpillu01
Co-authors: Cameron
Related Note: 1485313537044
Rationale for change

Current "extra section" is drastically incongruent with CDC data.

First edit: overdoses involving heroin have been declining since 2015. (source: https://www.cdc.gov/nchs/products/databriefs/db457.htm), based on nationally representative data. (page 4, figure 4, quote: Significant increasing trend [regarding heroin involved overdoses] from 2001 through 2015 with different rates of change over time, stable trend from 2015 through 2019, then significant decreasing
trend from 2019 through 2021, p < 0.05.)

Second edit: illicitly manufactured fentanyl (IMF) without concurrent prescription opioid use is attributed in ~40% of fatal overdoses (source: https://www.cdc.gov/drugoverdose/featured-topics/overdose-deaths-data.html) (IMF only, 19.8%. IMF and Cocaine, 10.5%. IMF and Heroin, 10.3%). Prescription opioids (taken with and without illicitly manufactured fentanyl) are seen in ~12.5% of overdose deaths.

Extra Extra
Text
What drug class is the most common cause of drug overdose death?

{{c1::Opioids (e.g., fentanyl)}}
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid


Sketchy



Watch Opioids, Naloxone, Naltrexone
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize

Physeo



Bootcamp
Watch associated Bootcamp video - Opioids

Watch associated Bootcamp video - Side Effects and Toxins: Pharmacological Toxicity and Treatment
OME

Additional Resources
Empty field
One by one
Empty field
!AK_UpdateTags::AnKing_Image::Mujeeb::Substance_intoxication #AK_Step1_v12::#FirstAid::13_Psych::02_Pathology::41_Psychoactive_drug_intoxication_and_withdrawal::*Depressants::Opioids #AK_Step2_v12::Original_decks::Zanki_Step_2::Psych::Step_1_Psych #AK_Step1_v12::#OME::Clinical::Pediatrics/Psychiatry #AK_Step2_v12::#SketchyPsych::10_Substance_Use/_Medication_Related_Disorders::01_Substance_Use_Overview #AK_Step1_v12::#Bootcamp::Psychiatry::08_Substance_Misuse::03_Opioids #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::01_Anesthetics_&_Analgesics::03_Opiates,_Naloxone,_Naltrexone #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::#Bootcamp::Pharmacology::04_Side_Effects_and_Toxins::02_Pharmacological_Toxicity_and_Treatment #AK_Step2_v12::#B&B::13_Psych::03_Substance_Abuse::02_Substance_Abuse_I #AK_Step1_v12::^Other::^HighYield::3-HighYield-temporary #AK_Step2_v12::#Resources_by_rotation::Psych::step1_psych_zanki #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::30_Opioid_Withdrawal,_Detoxification_and_Relapse_Prevention #AK_Step1_v12::#AMBOSS::vaaAmQ #AK_Step1_v12::#B&B::17_Psych::03_Substance_Use_Disorders::02_Opioids #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Psychiatry_/_Psychology #AK_Step1_v12::#Physeo::09_Pharm::14_Neuro::21_Opioid_Clinical_Use,_Mechanism_and_Overdose !AK_UpdateTags::Step1decks::Zanki-Step-Decks::Zanki-Psychiatry-/-Psychology #AK_Step2_v12::!Shelf::Psych::no_dupes #AK_Step1_v12::^Systems::Psychiatry #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::17_Full_Opioid_Agonists